Cargando…

Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy

PURPOSE: We aimed to compare the preventive effect of 5-day administration of aprepitant with single administration of fosaprepitant meglumine against nausea and vomiting symptoms due to highly emetogenic chemotherapy regimens comprising cisplatin (CDDP). METHODS: Subjects were inpatients who underw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ando, Yosuke, Hayashi, Takahiro, Ito, Kaori, Suzuki, Eri, Mine, Naoyuki, Miyamoto, Ayumi, Oya, Miyuki, Matsuda, Hidezo, Isaji, Ami, Nakanishi, Toru, Imaizumi, Kazuyoshi, Shibata, Tomoyuki, Okada, Tatsuyoshi, Sakurai, Kazuo, Naito, Kensei, Uyama, Ichiro, Kawada, Kenji, Takahashi, Hiroshi, Yamada, Shigeki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689777/ https://www.ncbi.nlm.nih.gov/pubmed/26206077 http://dx.doi.org/10.1007/s00520-015-2856-9

Ejemplares similares

Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting
por: Langford, Patrick, et al.
Publicado: (2010)

Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant
por: Olver, Ian N
Publicado: (2008)

Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives
por: Candelario, Nellowe, et al.
Publicado: (2016)

Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting
por: Chrisp, Paul
Publicado: (2007)

The efficacy of combination of ondansetron and aprepitant on preventing the radiotherapy-induced nausea and vomiting
por: Emami, Hamid, et al.
Publicado: (2015)

The efficacy of aprepitant for the prevention of postoperative nausea and vomiting: A meta-analysis
por: Liu, Yingchao, et al.
Publicado: (2023)

Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting
por: Celio, Luigi, et al.
Publicado: (2013)

Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial
por: Zhang, Zhonghan, et al.
Publicado: (2020)

Pharmacokinetics of Dexamethasone when Administered with Fosaprepitant for Chemotherapy-Induced Nausea and Vomiting and Differences in Dose-Dependent Antiemetic Effects
por: Shimamoto, Fukutaro, et al.
Publicado: (2021)

Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
por: Gao, Ai, et al.
Publicado: (2023)

Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial
por: Wang, De-Shen, et al.
Publicado: (2021)

Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer
por: Watanabe, Yuko, et al.
Publicado: (2021)

The Effects of Intravenous Fosaprepitant and Ondansetron for the Prevention of Postoperative Nausea and Vomiting in Neurosurgery Patients: A Prospective, Randomized, Double-Blinded Study
por: Tsutsumi, Yasuo M., et al.
Publicado: (2014)

A Comparison of Fosaprepitant and Ondansetron for Preventing Postoperative Nausea and Vomiting in Moderate to High Risk Patients: A Retrospective Database Analysis
por: Murakami, Chiaki, et al.
Publicado: (2017)

Economic Value of Fosaprepitant-Containing Regimen in the Prevention of Chemotherapy-Induced Nausea and Vomiting in China: Cost-Effectiveness and Budget Impact Analysis
por: Xu, Xinglu, et al.
Publicado: (2022)

Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting
por: Lim, Chae Seong, et al.
Publicado: (2013)

Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK
por: Humphreys, Samantha, et al.
Publicado: (2013)

Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer
por: Fujiwara, Satoe, et al.
Publicado: (2015)

Antiemetic regimen with aprepitant in the prevention of chemotherapy-induced nausea and vomiting: An updated systematic review and meta-analysis
por: Qiu, Tingting, et al.
Publicado: (2020)

Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
por: Kang, Jin Hyoung, et al.
Publicado: (2020)

Cost-Effectiveness of Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting: A Systematic Review of Published Articles
por: Qiu, Tingting, et al.
Publicado: (2021)

Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE
por: Hata, Akito, et al.
Publicado: (2022)

Fosaprepitant Weekly vs Every 3 Weeks for the Prevention of Concurrent Chemoradiotherapy–Induced Nausea and Vomiting: A Pilot Randomized Clinical Trial
por: Yang, Qi, et al.
Publicado: (2023)

Aprepitant in combination with palonosetron for the prevention of postoperative nausea and vomiting in female patients using intravenous patient-controlled analgesia
por: Yoo, Jae Hwa, et al.
Publicado: (2018)

Aprepitant for the management of nausea with inpatient IV dihydroergotamine
por: Chou, Denise E., et al.
Publicado: (2016)

Comparative Study Between Fosaprepitant and Palonosetron in the Prophylaxis of Postoperative Nausea and Vomiting in Women Undergoing Laparoscopic Cholecystectomy: Prospective, Randomized and Double-Blind Study
por: Braga, Estêvão Luiz Carvalho, et al.
Publicado: (2022)

The effect of aprepitant for the prevention of postoperative nausea and vomiting in patients undergoing gynecologic surgery with intravenous patient controlled analgesia using fentanyl: aprepitant plus ramosetron vs ramosetron alone
por: Lee, Se-Jin, et al.
Publicado: (2012)

Single center experience on efficacy and safety of Aprepitant for preventing chemotherapy-induced nausea and vomiting (CINV) in pediatric Hodgkin Lymphoma
por: Giagnuolo, Giovanna, et al.
Publicado: (2019)

Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study
por: Kawazoe, Hitoshi, et al.
Publicado: (2018)

A Comparison of the Efficacy of 5 mg Olanzapine and Aprepitant in the Prevention of Multiple-Day Cisplatin Chemotherapy-Induced Nausea and Vomiting
por: Liu, Guang, et al.
Publicado: (2022)

Overestimation of the effect of (fos)aprepitant on intravenous dexamethasone pharmacokinetics requires adaptation of the guidelines for children with chemotherapy-induced nausea and vomiting
por: Nijstad, A. Laura, et al.
Publicado: (2022)

Efficacy and safety of Aprepitant-containing triple therapy for the prevention and treatment of chemotherapy-induced nausea and vomiting: A meta-analysis
por: Zhang, Min, et al.
Publicado: (2023)

Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double‐blind, phase III study
por: Yang, L.Q., et al.
Publicado: (2017)

Effect of combinations of dexamethasone-ondansetron and dexamethasone-ondansetron-aprepitant versus aprepitant alone for early postoperative nausea and vomiting after day care gynaecological laparoscopy: A randomised clinical trial
por: Thanuja, Ingilala L, et al.
Publicado: (2021)

Palonosetron and aprepitant for the prevention of postoperative nausea and vomiting in patients indicated for laparoscopic gynaecologic surgery: a double-blind randomised trial
por: Moon, Hyoung Yong, et al.
Publicado: (2014)

Aprepitant in a Multimodal Approach for Prevention of Postoperative Nausea and Vomiting in High-Risk Patients: Is There Such a Thing as “Too Many Modalities”?
por: Hache, John J., et al.
Publicado: (2009)

Aprepitant plus palonosetron for the prevention of postoperative nausea and vomiting after breast cancer surgery: a double blind, randomized trial
por: Grigio, Thiago Ramos, et al.
Publicado: (2020)

5HT(3)RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy‐induced nausea and vomiting in colorectal cancer
por: Hayashi, Toshinobu, et al.
Publicado: (2020)

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2023)

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial(†)
por: Weinstein, C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4apktmobj0nke1e7jg2ds5m4oi